Regenetech(R), Inc., the tissue regeneration adult stem cell
company which has built upon NASA licensed technology, is pleased to
announce that it has signed a license covering the Republic of Korea
for its proprietary stem cell expansion technology, cellXpansion(TM),
with Korea Stem Cell Bank Co., Ltd. (KSCB). Financial terms for the
agreement were not disclosed.
Developing a significant and reliable technology for adult stem
cell growth and multiplication represents one of the most significant
barriers to widespread adult stem cell therapeutic use. Regenetech
believes its cellXpansion(TM) technology can help to achieve this.
Regenetech announced in October last year that it had achieved an
average 60-fold increase of CD34+38- peripheral blood progenitor cells
(adult stem cells) in as few as 6 days using its Intrifuge(TM)
cellXpansion(TM) system and the Company continues to research ways to
further expedite the process.
Regenetech also announced late last year the signing of a
country-exclusive license for its cellXpansion(TM) technology in
Mexico with Regenevita, a new Mexican company. The Company continues
to be actively engaged in licensing its technologies in the US and
abroad.
Dr. David Bonner, CEO of Regenetech, said: "We are delighted that
KSCB has chosen to partner with Regenetech and our strong
cellXpansion(TM) technology in order to expand stem cells.
Partnerships of this type are integral to the field and Regenetech´s
future development, and we are excited about the possibilities which
this agreement will facilitate."
For information on licensing opportunities with Regenetech,
contact rclark@regenetech.com.
